

# Marco Colleoni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5144897/publications.pdf>

Version: 2024-02-01

370  
papers

32,518  
citations

5574

82  
h-index

4645

170  
g-index

376  
all docs

376  
docs citations

376  
times ranked

23018  
citing authors

#	ARTICLE	IF	CITATIONS
1	The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients. <i>Anti-Cancer Drugs</i> , 2022, 33, e628-e634.	1.4	4
2	Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 137-145.	2.5	0
3	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 1.	5.2	17
4	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	1.6	88
5	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. <i>European Journal of Cancer</i> , 2022, 164, 39-51.	2.8	8
6	Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial. <i>Cancer Research</i> , 2022, 82, GS1-07-GS1-07.	0.9	0
7	Abstract OT1-12-07: A phase 2 study of chemotherapy de-escalation using a pathological response-guided strategy in patients with HER2-positive, low-risk early breast cancer: PHERGain-2. <i>Cancer Research</i> , 2022, 82, OT1-12-07-OT1-12-07.	0.9	0
8	Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. <i>European Journal of Cancer</i> , 2022, 164, 52-61.	2.8	0
9	Low-risk triple-negative breast cancers: Clinico-pathological and molecular features. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103643.	4.4	25
10	Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2 <sup>+</sup> Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. <i>Clinical Cancer Research</i> , 2022, 28, 851-859.	7.0	90
11	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2 <sup>+</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. <i>Clinical Cancer Research</i> , 2022, 28, 3433-3442.	7.0	65
12	Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 697-707.	2.5	8
13	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor <sup>+</sup> positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , 2021, 27, 504-512.	7.0	5
14	Clinical behavior of recurrent hormone receptor <sup>+</sup> positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1 <sup>+</sup> 98 clinical trial. <i>Cancer</i> , 2021, 127, 700-708.	4.1	2
15	Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. <i>European Journal of Surgical Oncology</i> , 2021, 47, 804-812.	1.0	91
16	Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 <sup>+</sup> Years of Follow-Up. <i>Oncologist</i> , 2021, 26, e749-e755.	3.7	33
17	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. <i>Journal of Clinical Oncology</i> , 2021, 39, 1448-1457.	1.6	171
18	ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 555-555.	1.6	1

#	ARTICLE	IF	CITATIONS
19	PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy. <i>Npj Breast Cancer</i> , 2021, 7, 47.	5.2	18
20	Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced breast cancer (ABC): Updated analyses from PALOMA-3. <i>Journal of Clinical Oncology</i> , 2021, 39, 1000-1000.	1.6	47
21	The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC). <i>Journal of Clinical Oncology</i> , 2021, 39, 524-524.	1.6	1
22	Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after treatment with endocrine therapy and CDK 4/6 inhibitors within randomized clinical trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 1059-1059.	1.6	0
23	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer: The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1518-1530.	1.6	153
24	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	9.4	79
25	Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. <i>Clinical Cancer Research</i> , 2021, 27, 5482-5491.	7.0	25
26	Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). <i>European Journal of Cancer</i> , 2021, 153, 223-233.	2.8	9
27	Genomic Profiling of Premenopausal HR+ and HER2-negative Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. <i>JCO Precision Oncology</i> , 2021, 5, 1408-1420.	3.0	15
28	Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations. <i>Breast</i> , 2021, 59, 94-101.	2.2	11
29	Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis. <i>Breast</i> , 2021, 59, 351-357.	2.2	1
30	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	1.2	354
31	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. <i>Breast</i> , 2021, 59, 327-338.	2.2	31
32	Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy. <i>Radiotherapy and Oncology</i> , 2021, 163, 128-135.	0.6	4
33	Breast Adjuvant Radiotherapy Amid the COVID-19 Crisis in a Hub Cancer Center, Lombardy, Italy. <i>Breast Care</i> , 2021, 16, 500-506.	1.4	3
34	Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1791.	7.1	56
35	Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. <i>BMJ</i> , The, 2021, 375, e066381.	6.0	53
36	Pegylated Liposomal Doxorubicin (Caelyx®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial. <i>Current Oncology</i> , 2021, 28, 5167-5178.	2.2	3

#	ARTICLE	IF	CITATIONS
37	Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. <i>Journal of Clinical Oncology</i> , 2020, 38, 1293-1303.	1.6	93
38	A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6149-6157.	7.0	29
39	EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 83.	5.0	6
40	Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 23-35.	2.5	21
41	Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy. <i>Breast</i> , 2020, 53, 138-142.	2.2	9
42	Estimation of historical control rate for a single arm de-escalation study – Application to the POSITIVE trial. <i>Breast</i> , 2020, 53, 1-7.	2.2	13
43	Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. <i>Breast Cancer Research</i> , 2020, 22, 27.	5.0	24
44	Multicentric breast cancer with heterogeneous histopathology: a multidisciplinary review. <i>Future Oncology</i> , 2020, 16, 395-412.	2.4	11
45	Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study. <i>Drug Safety</i> , 2020, 43, 233-242.	3.2	11
46	Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 347-359.	2.5	19
47	Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 503-503.	1.6	22
48	Comparison of StemPrintER, a novel biology-based genomic predictor of distant recurrence in breast cancer, with Oncotype DX in the TransATAC cohort.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1020-1020.	1.6	0
49	Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast.. <i>Journal of Clinical Oncology</i> , 2020, 38, e12570-e12570.	1.6	0
50	Integration of the stem cell biology-based genomic tool, StemPrintER, with clinicopathological parameters for the prediction of distant recurrence in ER+/HER2- breast cancer (BC) patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1057-1057.	1.6	0
51	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 419-430.	6.3	55
52	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1226-1238.	10.7	76
53	Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines. <i>British Journal of Cancer</i> , 2019, 121, 325-331.	6.4	25
54	Update on the Feasibility and Progress on Robotic Breast Surgery. <i>Annals of Surgical Oncology</i> , 2019, 26, 3046-3051.	1.5	63

#	ARTICLE	IF	CITATIONS
55	Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. Targeted Oncology, 2019, 14, 647-656.	3.6	12
56	Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. New England Journal of Medicine, 2019, 381, 307-316.	27.0	656
57	Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. Breast Cancer Research and Treatment, 2019, 176, 557-568.	2.5	10
58	Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study. EBioMedicine, 2019, 42, 352-362.	6.1	35
59	Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. Journal of Clinical Oncology, 2019, 37, 386-395.	1.6	16
60	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. British Journal of Cancer, 2019, 120, 959-967.	6.4	5
61	Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2019, 37, 1169-1178.	1.6	266
62	Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. Breast Cancer Research, 2019, 21, 30.	5.0	76
63	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b/2 trial. Lancet Oncology, The, 2019, 20, 371-382.	10.7	327
64	Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. Breast Cancer Research, 2019, 21, 153.	5.0	10
65	Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989410.	3.2	17
66	In-depth gene expression analysis of premenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.. Journal of Clinical Oncology, 2019, 37, 1018-1018.	1.6	5
67	Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.. Journal of Clinical Oncology, 2019, 37, 527-527.	1.6	4
68	Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.. Journal of Clinical Oncology, 2019, 37, LBA1008-LBA1008.	1.6	19
69	Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group (BIG) 1-98 sub-analyses.. Journal of Clinical Oncology, 2019, 37, 538-538.	1.6	0
70	Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the LILAC study.. Journal of Clinical Oncology, 2019, 37, 557-557.	1.6	1
71	Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer. Clinical Breast Cancer, 2018, 18, 328-335.	2.4	13
72	Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncology, The, 2018, 19, 249-256.	10.7	130

#	ARTICLE	IF	CITATIONS
73	Oncoplastic breast surgery for the management of ductal carcinoma in situ (DCIS): is it oncologically safe? A retrospective cohort analysis. <i>European Journal of Surgical Oncology</i> , 2018, 44, 957-962.	1.0	14
74	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 351-360.	2.5	5
75	Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes. <i>Clinical Breast Cancer</i> , 2018, 18, e401-e405.	2.4	21
76	Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. <i>Journal of Clinical Oncology</i> , 2018, 36, 1941-1948.	1.6	116
77	Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. <i>European Journal of Cancer</i> , 2018, 104, 21-31.	2.8	53
78	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1926-1936.	27.0	805
79	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1385-1393.	10.7	342
80	Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial. <i>Breast Care</i> , 2018, 13, 177-181.	1.4	31
81	Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 904-915.	10.7	648
82	Optimal management of luminal breast cancer: how much endocrine therapy is long enough?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877743.	3.2	12
83	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 122-137.	27.0	448
84	Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1335.	7.1	36
85	Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3. <i>Journal of Clinical Oncology</i> , 2018, 36, 1023-1023.	1.6	1
86	Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b ComPLEEment-1 trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1056-1056.	1.6	4
87	Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT. <i>Journal of Clinical Oncology</i> , 2018, 36, 503-503.	1.6	15
88	Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the SOLE trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 517-517.	1.6	1
89	Efficacy analyses of central laboratory pCR results from the LILAC study comparing the biosimilar ABP 980 and trastuzumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 583-583.	1.6	1
90	Estimation of historical control rate for a single arm de-escalation study: Application to the POSITIVE trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 552-552.	1.6	0



#	ARTICLE	IF	CITATIONS
91	Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1060-1060.	1.6	2
92	Metronomics in the neoadjuvant and adjuvant treatment of breast cancer. <i>Cancer Letters</i> , 2017, 400, 259-266.	7.2	14
93	Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER± metastatic breast cancer. <i>Nature Genetics</i> , 2017, 49, 444-450.	21.4	77
94	Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial. <i>Cancer Letters</i> , 2017, 400, 276-281.	7.2	34
95	Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. <i>Breast</i> , 2017, 34, 83-88.	2.2	22
96	Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. <i>Annals of Oncology</i> , 2017, 28, 2225-2232.	1.2	56
97	Adjuvant Systemic Therapies by Subtypes: Guidelines. , 2017, , 535-539.		0
98	Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. <i>Breast</i> , 2017, 31, 51-56.	2.2	109
99	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. <i>Annals of Oncology</i> , 2017, 28, 1700-1712.	1.2	844
100	Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 3113-3122.	1.6	101
101	Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1179-1188.	1.6	91
102	Reply to L. Moscetti. <i>Journal of Clinical Oncology</i> , 2017, 35, 1628-1628.	1.6	10
103	Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) in PALOMA-3.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1050-1050.	1.6	2
104	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 323-331.	2.5	100
105	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet Oncology</i> . The, 2016, 17, 425-439.	10.7	1,344
106	Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1601-1610.	1.6	100
107	Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. <i>Journal of Clinical Oncology</i> , 2016, 34, 2452-2459.	1.6	178
108	Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 2221-2231.	1.6	148

#	ARTICLE	IF	CITATIONS
109	Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice. <i>Cancer Treatment Communications</i> , 2016, 6, S1-S10.	0.4	10
110	Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VII. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 273-279.	0.8	22
111	Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). <i>Oncologist</i> , 2016, 21, 1165-1175.	3.7	183
112	Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. <i>Breast Cancer Research</i> , 2016, 18, 110.	5.0	22
113	Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Positive Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. <i>Journal of Clinical Oncology</i> , 2016, 34, 3400-3408.	1.6	65
114	Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. <i>Journal of Clinical Oncology</i> , 2016, 34, 927-935.	1.6	390
115	Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. <i>European Journal of Surgical Oncology</i> , 2016, 42, 361-368.	1.0	122
116	Neoadjuvant nab-paclitaxel in breast cancer: trial results and patient care. <i>Lancet Oncology</i> , The, 2016, 17, 265-266.	10.7	1
117	Oncoplastic Breast-Conserving Surgery for Tumors Larger than 2 Centimeters: Is it Oncologically Safe? A Matched-Cohort Analysis. <i>Annals of Surgical Oncology</i> , 2016, 23, 1852-1859.	1.5	69
118	Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease. <i>Ecancermedalscience</i> , 2015, 9, 544.	1.1	1
119	Sarcoidosis with bone involvement mimicking metastatic disease at 18F-FDG PET/CT: problem solving by diffusion whole-body MRI. <i>Ecancermedalscience</i> , 2015, 9, 537.	1.1	25
120	Nonrandomized Comparison between Concomitant and Sequential Chemoradiotherapy with Anthracyclines in Breast Cancer. <i>Tumori</i> , 2015, 101, 64-71.	1.1	3
121	Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study. <i>Clinical Breast Cancer</i> , 2015, 15, e257-e262.	2.4	2
122	Outcome and Medial Presentation of Breast Cancer: European Institute of Oncology Experience. <i>Clinical Breast Cancer</i> , 2015, 15, 440-447.	2.4	1
123	Clinical overview of metronomic chemotherapy in breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 631-644.	27.6	109
124	Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. <i>Lancet</i> , The, 2015, 386, 1341-1352.	18.7	1,072
125	Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2772-2779.	1.6	141
126	Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. <i>Lancet Oncology</i> , The, 2015, 16, 848-858.	10.7	145



#	ARTICLE	IF	CITATIONS
127	Second Axillary Sentinel Lymph Node Biopsy for Breast Tumor Recurrence: Experience of the European Institute of Oncology. <i>Annals of Surgical Oncology</i> , 2015, 22, 2372-2377.	1.5	39
128	Tailoring therapiesâ€”improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	1.2	1,449
129	Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 259-265.	2.4	34
130	Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. <i>Annals of Oncology</i> , 2015, 26, 2442-2449.	1.2	8
131	Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 275-286.	2.5	37
132	Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer. <i>Drugs</i> , 2015, 75, 1311-1321.	10.9	5
133	Picking the optimal endocrine adjuvant treatment for pre-menopausal women. <i>Breast</i> , 2015, 24, S11-S14.	2.2	6
134	Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 436-446.	27.0	588
135	Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2015, 26, 307-313.	1.2	43
136	Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 1002-1002.	1.6	5
137	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 463.	1.1	26
138	The role of maintenance strategies in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 152-156.	0.5	1
139	Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. <i>Breast Cancer Research</i> , 2014, 16, R65.	5.0	138
140	Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. <i>Annals of Oncology</i> , 2014, 25, 1979-1987.	1.2	122
141	Neoadjuvant chemotherapy for breast cancer: any progress?. <i>Lancet Oncology</i> , The, 2014, 15, 131-132.	10.7	22
142	Prevalence and Clinicopathologic Correlates of O6-Methylguanine-DNA Methyltransferase Methylation Status in Patients With Triple-Negative Breast Cancer Treated Preoperatively by Alkylating Drugs. <i>Clinical Breast Cancer</i> , 2014, 14, 285-290.	2.4	10
143	Outcome of Male Breast Cancer: A Matched Single-Institution Series. <i>Clinical Breast Cancer</i> , 2014, 14, 371-377.	2.4	32
144	Symptoms of endocrine treatment and outcome in the BIG 1-98 study. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 159-169.	2.5	36

#	ARTICLE	IF	CITATIONS
145	Targeting bone metastatic cancer: Role of the mTOR pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 248-254.	7.4	25
146	Survival Outcomes in Breast Cancer Patients With Low Estrogen/Progesterone Receptor Expression. <i>Clinical Breast Cancer</i> , 2014, 14, 258-264.	2.4	51
147	Outcomes of Patients With Breast Cancer Who Present With Ipsilateral Supraclavicular or Internal Mammary Lymph Node Metastases. <i>Clinical Breast Cancer</i> , 2014, 14, 53-60.	2.4	26
148	Metronomic therapy and breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2014, 40, 942-950.	7.7	44
149	Time to Initiation of Adjuvant Chemotherapy for Early Breast Cancer and Outcome: The Earlier, the Better?. <i>Journal of Clinical Oncology</i> , 2014, 32, 717-719.	1.6	15
150	Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 573-582.	2.5	9
151	Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 107-118.	27.0	621
152	Whole-body magnetic resonance imaging, metastatic breast cancer and pregnancy: A case report. <i>Breast</i> , 2014, 23, 295-296.	2.2	4
153	Metronomic Chemotherapy in Breast Cancers. , 2014, , 93-110.		2
154	Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 557-557.	1.6	3
155	ecancermedalscience. <i>Ecancermedalscience</i> , 2013, 7, 299.	1.1	17
156	Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23â€“01): a phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2013, 14, 297-305.	10.7	998
157	PET/CT and breast cancer subtypes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1301-1303.	6.4	5
158	The clinical relevance of micropapillary carcinoma of the breast: a caseâ€“control study. <i>Histopathology</i> , 2013, 63, 217-224.	2.9	53
159	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013, 24, 2206-2223.	1.2	2,805
160	Breast phyllodes tumor: A review of literature and a single center retrospective series analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 427-436.	4.4	150
161	Extended adjuvant chemotherapy in endocrine non-responsive disease. <i>Breast</i> , 2013, 22, S161-S164.	2.2	4
162	Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials. <i>Breast</i> , 2013, 22, 1094-1100.	2.2	73

#	ARTICLE	IF	CITATIONS
163	Therapeutic effect of $\beta$ -blockers in triple-negative breast cancer postmenopausal women. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 567-575.	2.5	113
164	Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 455-459.	2.5	19
165	Tailoring Adjuvant Treatments for the Individual Patient with Luminal Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 703-714.	2.2	5
166	Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": The CASA randomized trial. <i>Breast</i> , 2013, 22, 130-137.	2.2	48
167	Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. <i>Annals of Oncology</i> , 2013, 24, 661-668.	1.2	91
168	The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: Ready for prime time?. <i>Cancer Treatment Reviews</i> , 2013, 39, 886-890.	7.7	10
169	Pathological features and survival outcomes of very young patients with early breast cancer: How much is "very young"? <i>Breast</i> , 2013, 22, 1046-1051.	2.2	32
170	Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome. <i>Clinical Breast Cancer</i> , 2013, 13, 31-39.	2.4	128
171	Immunohistochemically Defined Subtypes and Outcome of Apocrine Breast Cancer. <i>Clinical Breast Cancer</i> , 2013, 13, 95-102.	2.4	52
172	Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 529-529.	1.6	4
173	Management of breast cancer during pregnancy: Results of a large registry from a single institution.. <i>Journal of Clinical Oncology</i> , 2013, 31, 589-589.	1.6	0
174	Breast cancer subtypes and outcome after local and regional relapse. <i>Annals of Oncology</i> , 2012, 23, 324-331.	1.2	57
175	Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3967-3975.	1.6	108
176	Is Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1260-1263.	1.6	60
177	HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH?. <i>Annals of Oncology</i> , 2012, 23, 1371-1372.	1.2	15
178	Outcome of special types of luminal breast cancer. <i>Annals of Oncology</i> , 2012, 23, 1428-1436.	1.2	99
179	Repeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the Best Candidates. <i>Annals of Surgical Oncology</i> , 2012, 19, 3771-3776.	1.5	65
180	Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report. <i>Breast Journal</i> , 2012, 18, 470-474.	1.0	25

#	ARTICLE	IF	CITATIONS
181	A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer. <i>Breast</i> , 2012, 21, 621-628.	2.2	5
182	Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 277-282.	2.5	61
183	Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 131-137.	2.5	35
184	Invasive lobular breast cancer: subtypes and outcome. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 713-723.	2.5	126
185	Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity. <i>Clinical Breast Cancer</i> , 2012, 12, 207-214.	2.4	59
186	Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. <i>Breast</i> , 2012, 21, 309-313.	2.2	25
187	Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 819-825.	2.5	64
188	Prognostic role of CA15.3 in 7942 patients with operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 317-326.	2.5	25
189	Intrinsic subtype and its clinical significance in early node-negative breast cancer: Results from two randomized trials of adjuvant chemoendocrine therapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 504-504.	1.6	0
190	Influence of Margin Status on Outcomes in Lobular Carcinoma. <i>Annals of Surgery</i> , 2011, 253, 580-584.	4.2	15
191	Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. <i>Annals of Oncology</i> , 2011, 22, 2201-2207.	1.2	84
192	Positive axillary sentinel lymph node: Is axillary dissection always necessary?. <i>Breast</i> , 2011, 20, S96-S98.	2.2	26
193	Local therapy for breast cancer in malignant lymphoma survivors. <i>Breast</i> , 2011, 20, S99-S103.	2.2	13
194	Adjuvant therapies for special types of breast cancer. <i>Breast</i> , 2011, 20, S153-S157.	2.2	27
195	Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer. <i>Breast</i> , 2011, 20, 34-38.	2.2	8
196	Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. <i>Breast</i> , 2011, 20, 319-323.	2.2	38
197	Sentinel Lymph Node Biopsy in Multicentric Breast Cancer: Five-Year Results in a Large Series from a Single Institution. <i>Annals of Surgical Oncology</i> , 2011, 18, 2879-2884.	1.5	24
198	Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 431-441.	2.5	28

#	ARTICLE	IF	CITATIONS
199	Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 713-720.	2.5	98
200	Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 867-875.	2.5	49
201	Timing of Radiotherapy and Outcome in Patients Receiving Adjuvant Endocrine Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 398-402.	0.8	32
202	Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. <i>Annals of Oncology</i> , 2011, 22, 2216-2226.	1.2	40
203	Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1117-1124.	1.6	134
204	Receptor status (ER, PgR and HER2) discordance between primary tumor and locoregional recurrence in breast cancer. <i>Annals of Oncology</i> , 2011, 22, 479-480.	1.2	6
205	Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1834-1841.	6.4	15
206	Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 211-218.	2.5	41
207	Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 689-699.	2.5	65
208	Phase II Trial of Combination of Pegylated Liposomal Doxorubicin, Cisplatin, and Infusional 5-Fluorouracil (CCF) Plus Trastuzumab as Preoperative Treatment for Locally Advanced and Inflammatory Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 483-488.	2.4	20
209	Breast-conserving surgery in 201 very young patients (<35 years). <i>Breast</i> , 2010, 19, 55-58.	2.2	21
210	Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer. <i>Breast</i> , 2010, 19, 128-132.	2.2	6
211	Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2966-2973.	1.6	121
212	Benefits and adverse effects of endocrine therapy. <i>Annals of Oncology</i> , 2010, 21, vii107-vii111.	1.2	28
213	Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. <i>Annals of Oncology</i> , 2010, 21, 245-254.	1.2	22
214	Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report. <i>Annals of Oncology</i> , 2010, 21, 667-668.	1.2	7
215	Letrozole. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 251-259.	3.3	20
216	Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. <i>Annals of Oncology</i> , 2010, 21, 1974-1981.	1.2	202

#	ARTICLE	IF	CITATIONS
217	International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?. Journal of the National Cancer Institute, 2010, 102, 456-463.	6.3	325
218	Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomy. Cancer Treatment Reviews, 2010, 36, 443-450.	7.7	25
219	A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer. European Journal of Cancer, 2010, 46, 2216-2224.	2.8	50
220	Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen. Journal of Clinical Oncology, 2010, 28, 509-518.	1.6	716
221	Metronomic Chemotherapy in Elderly Patients: Do Risks Exceed Benefits in Some Patients?. Tumori, 2009, 95, 130-130.	1.1	1
222	Clinical Relevance of <i>HER2</i> Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer. Journal of Clinical Oncology, 2009, 27, 5693-5699.	1.6	235
223	The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Annals of Oncology, 2009, 20, 1344-1351.	1.2	15
224	A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. Annals of Oncology, 2009, 20, 1178-1184.	1.2	36
225	Ductal Intraepithelial Neoplasia: Postsurgical Outcome for 1,267 Women Cared for in One Single Institution over 10 Years. Oncologist, 2009, 14, 201-212.	3.7	21
226	Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. Clinical Cancer Research, 2009, 15, 7652-7657.	7.0	102
227	Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of Oncology, 2009, 20, 1489-1498.	1.2	163
228	Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer. Breast, 2009, 18, 84-88.	2.2	21
229	Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. Breast, 2009, 18, S137-S140.	2.2	35
230	Lack of prognostic significance of <i>classical</i> lobular breast carcinoma: a matched, single institution series. Breast Cancer Research and Treatment, 2009, 117, 211-214.	2.5	42
231	Invasive ductal carcinoma of the breast with the <i>triple-negative</i> phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Research and Treatment, 2009, 116, 317-328.	2.5	172
232	Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Research and Treatment, 2009, 116, 359-369.	2.5	86
233	Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Research and Treatment, 2009, 113, 137-144.	2.5	53
234	Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. Breast Cancer Research and Treatment, 2009, 118, 385-394.	2.5	31



#	ARTICLE	IF	CITATIONS
235	Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. <i>Anti-Cancer Drugs</i> , 2009, 20, 197-203.	1.4	18
236	Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 965-971.	2.3	20
237	Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and) Tj ETQq1 1 0.784314 rgBT /Over weekly paclitaxel. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 667-672.	2.3	81
238	Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. <i>Supportive Care in Cancer</i> , 2008, 16, 67-74.	2.2	11
239	Daily low-dose aspirin in cancer patients with central venous catheter: new role for an old drug. <i>Supportive Care in Cancer</i> , 2008, 16, 313-314.	2.2	0
240	Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. <i>British Journal of Cancer</i> , 2008, 98, 25-33.	6.4	19
241	Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. <i>British Journal of Cancer</i> , 2008, 99, 1564-1571.	6.4	43
242	Role of Endocrine Responsiveness and HER2/neu Overexpression in Inflammatory Breast Cancer Treated with Multimodality Preoperative Therapy. <i>Breast Journal</i> , 2008, 14, 435-441.	1.0	7
243	Topoisomerase III± gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. <i>Breast</i> , 2008, 17, 506-511.	2.2	32
244	Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors. <i>Breast</i> , 2008, 17, 654-660.	2.2	8
245	Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents. <i>Cancer Cell</i> , 2008, 14, 263-273.	16.8	424
246	Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. <i>Annals of Oncology</i> , 2008, 19, 465-472.	1.2	89
247	Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 207-212.	6.3	215
248	Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 1972-1979.	1.6	133
249	Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4899-4905.	1.6	280
250	Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer. <i>British Journal of Cancer</i> , 2008, 98, 1745-1752.	6.4	21
251	Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 806-813.	1.6	68
252	Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. <i>Annals of Oncology</i> , 2008, 19, 1090-1096.	1.2	168

#	ARTICLE	IF	CITATIONS
253	Sentinel Node Biopsy Is Not a Standard Procedure in Ductal Carcinoma In Situ of the Breast. <i>Annals of Surgery</i> , 2008, 247, 315-319.	4.2	124
254	Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98. <i>Journal of Clinical Oncology</i> , 2007, 25, 486-492.	1.6	835
255	Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. <i>Annals of Oncology</i> , 2007, 18, 1632-1640.	1.2	92
256	Management of advanced breast cancer. <i>Annals of Oncology</i> , 2007, 18, vi74-vi76.	1.2	17
257	Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. <i>Annals of Oncology</i> , 2007, 18, 1177-1184.	1.2	8
258	Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. <i>Annals of Oncology</i> , 2007, 18, 1927-1934.	1.2	324
259	Role of fluorodeoxyglucose positron emission tomography in the staging of patients with breast cancer candidated to surgery. <i>Annals of Oncology</i> , 2007, 18, 394-395.	1.2	5
260	Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors. <i>Annals of Oncology</i> , 2007, 18, 288-292.	1.2	46
261	New Criteria for Selecting Elderly Patients for Breast Cancer Adjuvant Treatment Studies. <i>Oncologist</i> , 2007, 12, 952-959.	3.7	16
262	Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 5715-5722.	1.6	125
263	Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. <i>European Journal of Cancer</i> , 2007, 43, 660-675.	2.8	83
264	HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17. <i>European Journal of Cancer</i> , 2007, 43, 2339-2344.	2.8	54
265	Unnecessary axillary node dissections in the sentinel lymph node era. <i>European Journal of Cancer</i> , 2007, 43, 2664-2668.	2.8	22
266	CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. <i>Annals of Oncology</i> , 2007, 18, 701-708.	1.2	95
267	Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. <i>Cancer</i> , 2007, 110, 509-517.	4.1	36
268	Sentinel lymph node biopsy is feasible even after total mastectomy. <i>Journal of Surgical Oncology</i> , 2007, 95, 175-179.	1.7	35
269	Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. <i>British Journal of Cancer</i> , 2007, 97, 802-808.	6.4	67
270	Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2â€“T4 breast cancer. <i>Breast</i> , 2007, 16, 73-80.	2.2	14

#	ARTICLE	IF	CITATIONS
271	Results of chest wall resection for recurrent or locally advanced breast malignancies. <i>Breast</i> , 2007, 16, 297-302.	2.2	45
272	Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response. <i>Breast</i> , 2007, 16, 262-270.	2.2	11
273	Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter. <i>Supportive Care in Cancer</i> , 2007, 15, 1213-1217.	2.2	12
274	Factor V Leiden Mutation in Patients with Breast Cancer with a Central Venous Catheter: Risk of Deep Vein Thrombosis. <i>Supportive Cancer Therapy</i> , 2006, 3, 98-102.	0.3	15
275	Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. <i>Blood</i> , 2006, 108, 452-459.	1.4	242
276	Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2006, 17, 961-967.	1.4	91
277	A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2006, 17, 1201-1209.	1.4	11
278	Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. <i>BMC Cancer</i> , 2006, 6, 225.	2.6	103
279	Video-assisted management of malignant pleural effusion in breast carcinoma. <i>Cancer</i> , 2006, 106, 271-276.	4.1	29
280	Adjuvant Therapy in Elderly Patients with Early Breast Cancer. <i>Current Cancer Therapy Reviews</i> , 2006, 2, 315-325.	0.3	0
281	Reply to the Letter to the Editor on "Cost" opportunity analysis in clinical oncology: from the "wild west" to a correct integration of the disciplines, avoiding the "war of the worlds"™, by D. Tassinari et al. ( <i>Ann Oncol</i> 2006; 17: 877). <i>Annals of Oncology</i> , 2006, 17, 878.	1.2	1
282	Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. <i>Annals of Oncology</i> , 2006, 17, 232-238.	1.2	166
283	Primary systemic therapy on local advanced breast cancer, where are we going?. <i>Annals of Oncology</i> , 2006, 17, vii18-vii21.	1.2	3
284	Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. <i>Annals of Oncology</i> , 2006, 17, 1497-1503.	1.2	72
285	Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph Node-Positive Breast Cancer: International Breast Cancer Study Group Trial 13-93. <i>Journal of Clinical Oncology</i> , 2006, 24, 1332-1341.	1.6	215
286	Focusing on physical function limitations in elderly women surviving cancer: any opportunity for improvement?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 598-599.	4.3	5
287	Systemic Effects of Surgery: Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF- $\beta$ 2) in Patients with Breast Cancer Who Underwent Limited or Extended Surgery. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 35-40.	2.5	59
288	Treatment of advanced breast cancer: the good, the bad and the ugly. <i>Annals of Oncology</i> , 2005, 16, 1219-1221.	1.2	5

#	ARTICLE	IF	CITATIONS
289	Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. <i>Annals of Oncology</i> , 2005, 16, 1094-1099.	1.2	22
290	Site of Primary Tumor Has a Prognostic Role in Operable Breast Cancer: The International Breast Cancer Study Group Experience. <i>Journal of Clinical Oncology</i> , 2005, 23, 1390-1400.	1.6	74
291	Can tamoxifen relieve motion sickness?. <i>Annals of Oncology</i> , 2005, 16, 1713-1714.	1.2	3
292	Size of Breast Cancer Metastases in Axillary Lymph Nodes: Clinical Relevance of Minimal Lymph Node Involvement. <i>Journal of Clinical Oncology</i> , 2005, 23, 1379-1389.	1.6	153
293	Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. <i>Annals of Oncology</i> , 2005, 16, 716-725.	1.2	18
294	Adjuvant Endocrine Therapy for Premenopausal Women With Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1736-1750.	1.6	79
295	Prophylaxis for Venous Thromboembolism in Cancer Patients With a Central Vein Catheter: New Tones for an Old Song. <i>Journal of Clinical Oncology</i> , 2005, 23, 7243-7244.	1.6	3
296	Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. ( <i>Ann Oncol</i> 2004; 15: 1543-1550): and in humans?. <i>Annals of Oncology</i> , 2005, 16, 673.	1.2	6
297	Prediction of cancer outcome with microarrays. <i>Lancet, The</i> , 2005, 365, 1683.	13.7	14
298	Prediction of cancer outcome with microarrays. <i>Lancet, The</i> , 2005, 365, 1685-1686.	13.7	4
299	Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. <i>Lancet, The</i> , 2005, 366, 1108-1110.	13.7	118
300	ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC). <i>Annals of Oncology</i> , 2005, 16, i10-i12.	1.2	26
301	Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. <i>Annals of Oncology</i> , 2004, 15, 590-593.	1.2	52
302	Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors. <i>Clinical Cancer Research</i> , 2004, 10, 6622-6628.	7.0	333
303	Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you) Tj ETQq1 1 0.784314 rgBT /Over	1.2	2
304	Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. <i>Annals of Oncology</i> , 2004, 15, 1633-1639.	1.2	65
305	Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. <i>Cancer</i> , 2004, 101, 905-912.	4.1	64
306	Breast carcinoma in elderly women. <i>Cancer</i> , 2004, 101, 1302-1310.	4.1	176

#	ARTICLE	IF	CITATIONS
307	Adjuvant Therapy for Very Young Women with Breast Cancer: Response According to Biologic and Endocrine Features. <i>Clinical Breast Cancer</i> , 2004, 5, 125-130.	2.4	15
308	Long-term Results of Intrapericardial Chemotherapeutic Treatment of Malignant Pericardial Effusions With Thiotepa. <i>Chest</i> , 2004, 126, 1412-1416.	0.8	67
309	Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. <i>Anticancer Research</i> , 2004, 24, 1261-6.	1.1	26
310	Adjuvant systemic therapies for patients with breast cancer: Endocrine responsiveness and effects of chemotherapy. <i>Current Problems in Cancer</i> , 2003, 27, 13-16.	2.0	0
311	Preoperative systemic treatment: prediction of responsiveness. <i>Breast</i> , 2003, 12, 538-542.	2.2	31
312	Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. <i>Annals of Oncology</i> , 2003, 14, 1477-1483.	1.2	9
313	Adjuvant Chemotherapy Followed by Goserelin Versus Either Modality Alone for Premenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1833-1846.	6.3	261
314	Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. <i>Annals of Oncology</i> , 2003, 14, 843-848.	1.2	27
315	Systemic treatments for women with breast cancer: outcome with relation to screening for the disease. <i>Annals of Oncology</i> , 2003, 14, 1212-1214.	1.2	26
316	Adjuvant Chemotherapy in Breast Cancer: Back to the Future. <i>Oncology Research and Treatment</i> , 2003, 26, 111-112.	1.2	0
317	Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. <i>Annals of Oncology</i> , 2002, 13, 73-80.	1.2	421
318	Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. <i>Annals of Oncology</i> , 2002, 13, 895-902.	1.2	34
319	Very young women (<35 years) with operable breast cancer: features of disease at presentation. <i>Annals of Oncology</i> , 2002, 13, 273-279.	1.2	301
320	Perioperative Chemotherapy in Patients With Node-Negative Postmenopausal Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 2210-2212.	1.6	0
321	New technologies for diagnosis and treatment of breast cancer: meeting highlights from the Third Milan Breast Cancer Conference (Milan, June 13-15, 2001). <i>Breast</i> , 2002, 11, 185.	2.2	0
322	Special issues of systemic treatments. <i>Breast</i> , 2002, 11, 200-201.	2.2	0
323	Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. <i>British Journal of Cancer</i> , 2002, 86, 1705-1714.	6.4	59
324	Bone scan had no role in the staging of 765 consecutive operable T1-2N0 breast cancer patients without skeletal symptoms. <i>Annals of Oncology</i> , 2001, 12, 724-725.	1.2	11

#	ARTICLE	IF	CITATIONS
325	Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study. <i>Annals of Oncology</i> , 2001, 12, 95-100.	1.2	17
326	Influence of Endocrine-Related Factors on Response to Perioperative Chemotherapy for Patients With Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 4141-4149.	1.6	81
327	Early Start of Adjuvant Chemotherapy May Improve Treatment Outcome for Premenopausal Breast Cancer Patients With Tumors not Expressing Estrogen Receptors. <i>Journal of Clinical Oncology</i> , 2000, 18, 584-584.	1.6	181
328	Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. <i>Annals of Oncology</i> , 2000, 11, 1057-1060.	1.2	88
329	Introducing taxanes in the adjuvant treatment of breast cancer: expectations and reality. <i>Breast</i> , 2000, 9, 134-138.	2.2	0
330	Intrapericardial Treatment of Neoplastic Pericardial Effusions. <i>Herz</i> , 2000, 25, 787-793.	1.1	39
331	Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): Is prophylaxis required?. <i>Annals of Oncology</i> , 2000, 11, 117-118.	1.2	12
332	Depression and degree of acceptance of adjuvant cytotoxic drugs. <i>Lancet, The</i> , 2000, 356, 1326-1327.	13.7	274
333	Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF regimen). <i>Annals of Oncology</i> , 1999, 10, 1394-1395.	1.2	4
334	Pharmacokinetics of Oral Doxifluridine in Patients with Colorectal Cancer. <i>Tumori</i> , 1999, 85, 47-50.	1.1	4
335	Prediction of response to primary chemotherapy for operable breast cancer. <i>European Journal of Cancer</i> , 1999, 35, 574-579.	2.8	89
336	Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. <i>Lancet, The</i> , 1999, 354, 130-131.	13.7	40
337	Primary chemotherapy in operable breast cancer with favorable prognostic factors: A pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). <i>Annals of Oncology</i> , 1999, 10, 993-996.	1.2	20
338	Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: Still a question?. <i>Cancer Treatment Reviews</i> , 1998, 24, 15-26.	7.7	11
339	Pre-operative chemotherapy and radiotherapy in breast cancer. <i>European Journal of Cancer</i> , 1998, 34, 641-645.	2.8	26
340	Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. <i>European Journal of Cancer</i> , 1998, 34, 1693-1700.	2.8	59
341	Practical Considerations in the Treatment of Hepatocellular Carcinoma. <i>Drugs</i> , 1998, 55, 367-382.	10.9	23
342	Radiotherapy and Chemotherapy in High-Risk Breast Cancer. <i>New England Journal of Medicine</i> , 1998, 338, 329-333.	27.0	12



#	ARTICLE	IF	CITATIONS
343	Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: Are all CMFs alike?. <i>Annals of Oncology</i> , 1998, 9, 489-493.	1.2	49
344	Oesophageal cancer treatment: Studies, strategies and facts. <i>Annals of Oncology</i> , 1998, 9, 951-962.	1.2	61
345	Assessment of response in primary chemotherapy for breast cancer. <i>Annals of Oncology</i> , 1998, 9, 1140-1141.	1.2	0
346	Activity and Tolerability of Courses of Intra-Arterial Chemotherapy Followed by Chemoembolization in Unresectable Hepatocellular Carcinoma. <i>Tumori</i> , 1998, 84, 673-676.	1.1	2
347	Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma. <i>European Journal of Cancer</i> , 1997, 33, 56-60.	2.8	6
348	Feasibility of paclitaxel in a patient with anthracycline-induced congestive heart failure. <i>European Journal of Cancer</i> , 1997, 33, 321-322.	2.8	0
349	A Randomized Phase II Trial of Two Different Schedules of Mitomycin C and Vinorelbine in Pretreated Breast Cancer. <i>Oncology</i> , 1997, 54, 438-439.	1.9	2
350	Activity of Combination Chemotherapy in Brain Metastases from Breast and Lung Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 303-307.	1.3	26
351	Phase II Study of Estramustine, Oral Etoposide, and Vinorelbine in Hormone-Refractory Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 383-386.	1.3	41
352	Phase II Study of Oral L-Leucovorin, 120-Hour Fluorouracil Infusion and Carboplatin in Advanced Pancreatic Cancer. <i>Tumori</i> , 1996, 82, 573-575.	1.1	5
353	A Dose-Escalating Study of Carboplatin Combined with Vinorelbine in Non-Small-Cell Lung Cancer. <i>Oncology</i> , 1996, 53, 364-368.	1.9	11
354	Primary Cutaneous Rhabdomyosarcoma in Adults-Description of an Uncommon Aggressive Disease. <i>Acta Oncologica</i> , 1996, 35, 494-495.	1.8	8
355	Mitoxantrone, Fluorouracil plus L-Leucovorin, and Vinorelbine in Pretreated Advanced Breast Cancer. <i>Oncology</i> , 1995, 52, 435-438.	1.9	4
356	Megestrol Acetate in Unresectable Hepatocellular Carcinoma. <i>Tumori</i> , 1995, 81, 351-353.	1.1	12
357	Clinical Development of new Fluoropyrimidines: A Major Improvement in Colorectal Cancer Treatment?. <i>Tumori</i> , 1995, 81, 303-307.	1.1	1
358	Evidence of responsiveness to chemotherapy in aggressive Rosai-Dorfman disease. <i>European Journal of Cancer</i> , 1995, 31, 424.	2.8	3
359	Evaluation of Ki-67 expression as a prognostic feature in hepatocellular carcinoma in cirrhosis. <i>European Journal of Cancer</i> , 1995, 31, 1547-1548.	2.8	5
360	Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer. <i>European Journal of Cancer</i> , 1995, 31, 2426-2427.	2.8	6

#	ARTICLE	IF	CITATIONS
361	Medical Treatment of Hepatocellular Carcinoma: Any Progress?. Tumori, 1994, 80, 315-326.	1.1	19
362	Results of a Salvage Regimen in Refractory or Relapsed Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1994, 14, 121-128.	1.3	41
363	Goserelin in Premenopausal Advanced Breast Cancer: Clinical and Endocrine Evaluation of Responsive Patients. Oncology, 1994, 51, 262-269.	1.9	19
364	Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. European Journal of Cancer, 1993, 29, 1658-1663.	2.8	28
365	Fluorouracil plus Folinic Acid in Metastatic Adenocarcinoma of Unknown Primary Site Suggestive of a Gastrointestinal Primary. Tumori, 1993, 79, 116-118.	1.1	5
366	Subcutaneous Low-Dose Interleukin-2 plus Alpha Interferon in Advanced Malignant Melanoma. Tumori, 1993, 79, 187-190.	1.1	3
367	Classic Kaposi's Sarcoma: A Review of 90 Cases. Journal of Dermatology, 1992, 19, 548-552.	1.2	19
368	Adjuvant Chemotherapy for Cancer of Gastrointestinal Tract: A Critical Review. Tumori, 1992, 78, 228-234.	1.1	4
369	Reversal of Resistance to Doxifluridine and Fluorouracil in Metastatic Colorectal Cancer: The Role of High-Dose Folinic Acid. Tumori, 1992, 78, 258-261.	1.1	1
370	Well-Differentiated Neuroendocrine Carcinoma of the Lung: A Case Report. Tumori, 1991, 77, 282-284.	1.1	1